Equities Analysts Set Expectations for CGEM FY2025 Earnings

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Equities researchers at Leerink Partnrs raised their FY2025 earnings estimates for Cullinan Therapeutics in a report issued on Monday, November 18th. Leerink Partnrs analyst A. Berens now forecasts that the company will earn ($4.11) per share for the year, up from their previous estimate of ($4.16). The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.12) per share. Leerink Partnrs also issued estimates for Cullinan Therapeutics’ FY2026 earnings at ($3.06) EPS and FY2027 earnings at ($0.06) EPS.

CGEM has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and set a $28.00 target price on shares of Cullinan Therapeutics in a report on Wednesday, October 16th. UBS Group began coverage on Cullinan Therapeutics in a research report on Thursday, October 24th. They set a “buy” rating and a $30.00 target price for the company. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Cullinan Therapeutics in a research report on Wednesday, September 18th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, Cullinan Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $31.67.

Cullinan Therapeutics Trading Down 2.6 %

NASDAQ:CGEM opened at $13.10 on Wednesday. The stock’s 50-day moving average is $16.35 and its 200-day moving average is $18.58. The stock has a market cap of $762.79 million, a P/E ratio of -4.61 and a beta of -0.12. Cullinan Therapeutics has a 1-year low of $7.64 and a 1-year high of $30.19.

Cullinan Therapeutics (NASDAQ:CGEM) last issued its earnings results on Thursday, November 7th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.09.

Insider Buying and Selling

In related news, insider Jennifer Michaelson sold 8,000 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $15.64, for a total transaction of $125,120.00. Following the transaction, the insider now directly owns 107,942 shares of the company’s stock, valued at approximately $1,688,212.88. This represents a 6.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 6.07% of the stock is owned by insiders.

Institutional Investors Weigh In On Cullinan Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its holdings in shares of Cullinan Therapeutics by 31.0% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,599 shares of the company’s stock worth $44,000 after purchasing an additional 615 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Cullinan Therapeutics by 3.7% during the first quarter. Price T Rowe Associates Inc. MD now owns 22,842 shares of the company’s stock worth $390,000 after acquiring an additional 820 shares in the last quarter. Amalgamated Bank raised its holdings in shares of Cullinan Therapeutics by 97.3% in the 3rd quarter. Amalgamated Bank now owns 1,768 shares of the company’s stock worth $30,000 after acquiring an additional 872 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Cullinan Therapeutics by 3.5% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,911 shares of the company’s stock valued at $1,187,000 after acquiring an additional 2,377 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Cullinan Therapeutics by 73.3% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,883 shares of the company’s stock valued at $155,000 after purchasing an additional 3,758 shares during the last quarter. Institutional investors own 86.31% of the company’s stock.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.